title: Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity.
abstract: BACKGROUND
  This study was conducted to determine whether increased body mass index (BMI) affects oral contraceptive (OC) pharmacokinetics and suppression of hypothalamic-pituitary-ovarian (HPO) axis activity.
  
  
  METHODS
  Ovulatory reproductive-age women with normal weight (BMI <25 kg/m(2); n=10) and with obesity (BMI >30 kg/m(2); n=10) received OCs for two cycles (prospective cohort). Subjects were admitted for two 48-h inpatient stays at the beginning and end of the hormone-free interval. Ethinyl estradiol and levonorgestrel (LNG) levels were evaluated during both inpatient stays. Gonadotropin pulsatility (follicle-stimulating hormone and luteinizing hormone) was measured during the second inpatient stay. Estradiol (E(2)) and progesterone (P) were measured daily during inpatient stays and twice per week in Cycle 2.
  
  
  RESULTS
  BMI was greater in the obese compared to the normal-BMI group [37.3 kg/m(2) (SD, 6.0) vs. 21.9 kg/m(2) (SD, 1.6); p<.05]. The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women. There were no significant differences in volume of distribution between groups. LH pulse parameters did not differ statistically between groups but trended toward greater HPO activity in the obese group. Additionally, more obese (6/10 vs. 3/10 normal BMI, p>.05) women exhibited E(2) levels consistent with development of a dominant follicle and P levels consistent with ovulation (2/10 vs. 1/10) during Cycle 2.
  
  
  CONCLUSIONS
  Compared to women with normal BMI, obese women exhibit differences in OC pharmacokinetics that are associated with greater HPO activity.
authors.affiliation: Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR 97239, USA. edelmana@ohsu.edu
authors.forename: Alison B
authors.initials: AB
authors.lastname: Edelman
authors.forename: Nichole E
authors.initials: NE
authors.lastname: Carlson
authors.forename: Ganesh
authors.initials: G
authors.lastname: Cherala
authors.forename: Myrna Y
authors.initials: MY
authors.lastname: Munar
authors.forename: Richard L
authors.initials: RL
authors.lastname: Stouffer
authors.forename: Judy L
authors.initials: JL
authors.lastname: Cameron
authors.forename: Frank Z
authors.initials: FZ
authors.lastname: Stanczyk
authors.forename: Jeffrey T
authors.initials: JT
authors.lastname: Jensen
mesh_terms: D000293:Adolescent; D000328:Adult; D015992:Body Mass Index; D016022:Case-Control Studies; D003277:Contraceptives, Oral, Combined / Q000493:pharmacokinetics*; D004958:Estradiol / Q000097:blood; D004997:Ethinyl Estradiol / Q000493:pharmacokinetics*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology*; D016912:Levonorgestrel / Q000493:pharmacokinetics*; D007986:Luteinizing Hormone / Q000097:blood; D009765:Obesity / Q000097:blood / Q000503:physiopathology*; D055815:Young Adult
chemical_list: D003277:Contraceptives, Oral, Combined; D004997:Ethinyl Estradiol; D004958:Estradiol; D016912:Levonorgestrel; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone